- Home
- MAMO vs TLSA Comparison
MAMO vs TLSA Comparison
Compare MAMO & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAMO
- TLSA
- Stock Information
- Founded
- MAMO 2008
- TLSA 2013
- Country
- MAMO United States
- TLSA United Kingdom
- Employees
- MAMO 122
- TLSA N/A
- Industry
- MAMO
- TLSA Biotechnology: Pharmaceutical Preparations
- Sector
- MAMO
- TLSA Health Care
- Exchange
- MAMO NYSE
- TLSA Nasdaq
- Market Cap
- MAMO 129.5M
- TLSA 87.8M
- IPO Year
- MAMO 2024
- TLSA 2000
- Fundamental
- Price
- MAMO $3.13
- TLSA $0.67
- Analyst Decision
- MAMO
- TLSA
- Analyst Count
- MAMO 0
- TLSA 0
- Target Price
- MAMO N/A
- TLSA N/A
- AVG Volume (30 Days)
- MAMO 43.7K
- TLSA 1.2M
- Earning Date
- MAMO 11-15-2024
- TLSA 02-11-2025
- Dividend Yield
- MAMO N/A
- TLSA N/A
- EPS Growth
- MAMO N/A
- TLSA N/A
- EPS
- MAMO 0.18
- TLSA N/A
- Revenue
- MAMO $130,710,373.00
- TLSA N/A
- Revenue This Year
- MAMO N/A
- TLSA N/A
- Revenue Next Year
- MAMO N/A
- TLSA N/A
- P/E Ratio
- MAMO $17.08
- TLSA N/A
- Revenue Growth
- MAMO 30.14
- TLSA N/A
- 52 Week Low
- MAMO $2.42
- TLSA $0.41
- 52 Week High
- MAMO $4.66
- TLSA $1.74
- Technical
- Relative Strength Index (RSI)
- MAMO N/A
- TLSA 41.47
- Support Level
- MAMO N/A
- TLSA $0.64
- Resistance Level
- MAMO N/A
- TLSA $0.74
- Average True Range (ATR)
- MAMO 0.00
- TLSA 0.09
- MACD
- MAMO 0.00
- TLSA -0.00
- Stochastic Oscillator
- MAMO 0.00
- TLSA 12.35
About MAMO MASSIMO GROUP
Massimo Group is engaged in the mid-tier band the (Mid-Tier Band) of the Powersports Vehicles and Boats Industry. It manufacture, import and distribute a diversified portfolio of products divided into two main lines: a motor sports brand consisting of utility terrain vehicles (UTVs), all-terrain vehicles (ATVs), motorcycles, scooters, golf carts and a juvenile line from go karts to balance bikes; and a motor boat line consisting of pontoon and tritoon boats (Pontoon Boats).
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.